Literature DB >> 3280732

Morphology and development of Rift Valley fever virus in Vero cell cultures.

D S Ellis1, P V Shirodaria, E Fleming, D I Simpson.   

Abstract

Rift Valley fever virus (RVFV) grown in vero cell cultures has a completed replication cycle within 13 hours. The first signs are the appearance of intranuclear fibrillar rods, followed by aggregations of precursor viral material in host cell cytoplasm and viral nucleocapsids budding into vacuoles associated with the Golgi apparati. Mature particles, liberated by the disintegration of vero cells, contained ribosomelike structures within the nucleocapsid, which was surrounded by a typical unit membrane through which were inserted some 350-375 surface spikes whose inner ends were incorporated into the nucleocapsid structure. In the negatively stained material, the overall diameter of the virion was 90-110 nm; the spikes were 10-18 nm in length and 5 nm in diameter.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3280732     DOI: 10.1002/jmv.1890240205

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  16 in total

1.  In vitro and in vivo efficacy of a Rift Valley fever virus vaccine based on pseudovirus.

Authors:  Jian Ma; Ruifeng Chen; Weijin Huang; Jianhui Nie; Qiang Liu; Youchun Wang; Xiaoming Yang
Journal:  Hum Vaccin Immunother       Date:  2019-06-20       Impact factor: 3.452

2.  Chitosan and chitosan nanoparticles as adjuvant in local Rift Valley Fever inactivated vaccine.

Authors:  Ashgan F El-Sissi; Farida H Mohamed; Nadia M Danial; Ali Q Gaballah; Korany A Ali
Journal:  3 Biotech       Date:  2020-02-04       Impact factor: 2.406

3.  Polyamine Depletion Inhibits Bunyavirus Infection via Generation of Noninfectious Interfering Virions.

Authors:  Vincent Mastrodomenico; Jeremy J Esin; Marion L Graham; Patrick M Tate; Grant M Hawkins; Zachary J Sandler; David J Rademacher; Thomas M Kicmal; Courtney N Dial; Bryan C Mounce
Journal:  J Virol       Date:  2019-06-28       Impact factor: 5.103

4.  The carboxy-terminal acidic domain of Rift Valley Fever virus NSs protein is essential for the formation of filamentous structures but not for the nuclear localization of the protein.

Authors:  F Z Yadani; A Kohl; C Préhaud; A Billecocq; M Bouloy
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

5.  Enhanced detection of Rift Valley fever virus using molecular assays on whole blood samples.

Authors:  Allen Grolla; Masfique Mehedi; Robbin Lindsay; Catharine Bosio; Adriano Duse; Heinz Feldmann
Journal:  J Clin Virol       Date:  2012-05-24       Impact factor: 3.168

6.  A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity.

Authors:  David H Holman; Adam Penn-Nicholson; Danher Wang; Jan Woraratanadharm; Mary-Katherine Harr; Min Luo; Ellen M Maher; Michael R Holbrook; John Y Dong
Journal:  Clin Vaccine Immunol       Date:  2009-09-23

7.  Rift valley fever virus infection of human cells and insect hosts is promoted by protein kinase C epsilon.

Authors:  Claire Marie Filone; Sheri L Hanna; M Cecilia Caino; Shelly Bambina; Robert W Doms; Sara Cherry
Journal:  PLoS One       Date:  2010-11-24       Impact factor: 3.240

8.  Ultrastructural studies on the replication and morphogenesis of Nairobi sheep disease virus, a Nairovirus.

Authors:  P M Rwambo; M K Shaw; F R Rurangirwa; J C DeMartini
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

9.  Three-dimensional organization of Rift Valley fever virus revealed by cryoelectron tomography.

Authors:  Alexander N Freiberg; Michael B Sherman; Marc C Morais; Michael R Holbrook; Stanley J Watowich
Journal:  J Virol       Date:  2008-08-20       Impact factor: 5.103

10.  Rift Valley fever risk map model and seroprevalence in selected wild ungulates and camels from Kenya.

Authors:  Seth C Britch; Yatinder S Binepal; Mark G Ruder; Henry M Kariithi; Kenneth J Linthicum; Assaf Anyamba; Jennifer L Small; Compton J Tucker; Leonard O Ateya; Abuu A Oriko; Stephen Gacheru; William C Wilson
Journal:  PLoS One       Date:  2013-06-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.